| Long Non-coding RNAs in Precision Oncology: Mechanistic Insights and Their Potential as Biomarkers and Therapeutic Targets |
| Paper ID : 1236-IGA |
| Authors |
|
Hesam Aminian *, parinaz khanjanpoor University of Eastern Piedmont "Amedeo Avogadro" |
| Abstract |
| Background and Aim: Long non-coding RNAs (lncRNAs) have gained attention for their regulatory roles in cancer biology, influencing tumor progression and treatment response. This review aims to summarize mechanistic insights into lncRNAs in precision oncology and assess their potential as biomarkers and therapeutic targets. Materials and Methods: A systematic literature search was performed using keywords such as "long non-coding RNA," "biomarker," "therapeutic target," and "cancer" across PubMed and Google Scholar. Inclusion criteria were peer-reviewed articles published in English between 2015 and 2025, excluding conference proceedings. Results: LncRNAs exhibit cancer- and tissue-specific expression patterns, making them promising diagnostic and prognostic biomarkers. They regulate gene expression through transcriptional, post-transcriptional, and epigenetic mechanisms, impacting pathways like MAPK, Wnt, and PI3K/AKT. Several lncRNAs are detectable in body fluids, enabling non-invasive cancer detection. Therapeutically, approaches such as antisense oligonucleotides and CRISPR-Cas9 targeting of lncRNAs show potential to overcome drug resistance and improve treatment specificity. Clinically, lncRNAs like PCA3 have been approved as biomarkers, highlighting translational progress. Conclusion: LncRNAs represent a novel and promising class of molecules in precision oncology, offering improved biomarkers and innovative therapeutic targets. While challenges remain in delivery and mechanistic clarity, ongoing research supports their integration into personalized cancer diagnosis and therapy, ultimately enhancing patient outcomes. |
| Keywords |
| Long non-coding RNA, lncRNA, Precision oncology, Cancer biomarker, Personalized therapy |
| Status: Accepted |
